CLGN · CollPlant Biotechnologies Ltd Ordinary Shares
View on chartInsiders & Stakes
| Rotem Eran Deputy CEO and CFO | ▲ Buy | Grant | 516,372 Shares held | 9/3/2026 | View profile |
| Abelis Bar Berta VP Legal | ▲ Buy | Grant | 206,441 Shares held | 9/3/2026 | View profile |
Transaction History
| Rotem Eran | ▲ Buy | Grant | 510,372 | $0 | 9/3/2026 |
| Abelis Bar Berta | ▲ Buy | Grant | 201,141 | $0 | 9/3/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
CollPlant Q2 Earnings Miss Estimates Significantly
CollPlant Biotechnologies reported second-quarter results that fell short of analyst expectations. The company posted an adjusted loss of $1.69 per share, missing the estimate of $0.24, while sales of $108,000 were well below the projected $1.466 million. This significant gap between actual performance and market forecasts highlights current operational challenges for the firm.
CollPlant Q2 Earnings Miss Estimates Significantly. CollPlant Biotechnologies reported second-quarter results that fell short of analyst expectations. The company posted an adjusted loss of $1.69 per share, missing the estimate of $0.24, while sales of $108,000 were well below the projected $1.466 million. This significant gap between actual performance and market forecasts highlights current operational challenges for the firm.